{
    "nctId": "NCT00496795",
    "briefTitle": "Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer",
    "officialTitle": "Molecular Markers Predictive Response to Dose Dense Chemotherapy With Epirubicin and Docetaxel in Sequences for Locally Advanced Breast Cancer.",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Stage III Breast Cancer AJCC V7",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "To correlate molecular parameters to objective response to each of the 2 regimens applied.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Primary breast cancer \\>4cm in diameter and / or lymph node status N2-3.\n* Age 65 years or younger\n* \"Limited\" distant metastases allowed, but patients with massive distant metastases should be excluded\n* Willing to participate in the study\n\nExclusion Criteria:\n\n* Known allergy toward any of the cytotoxic compounds to be administered (epirubicin and doxorubicin)\n* Liver enzymes \\> 2 times upper normal limit or bilirubin \\> 3 times upper normal limit\n* Other medical conditions making them unfit for dose-dense therapy\n* Cardiac insufficiency; for patients not to receive trastuzumab, decision whether to exclude such patients will be at the physicians discretion. Considering patients with HER-2 positive tumors who should have trastuzumab, exclusion criteria will be according to the NBCG (Norwegian Breast Cancer Group) general guidelines (www.NBCG.net).",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}